Rapid Evacuation and Access of
Cerebral Hemorrhage
REACH is an adaptive, prospective, multi-center, randomized, controlled clinical trial and companion registry to evaluate the safety and effectiveness of minimally invasive parafasicular surgery in patients with intracerebral hemorrhage in the anterior basal ganglia.
TRIAL
REGISTRY
The REACH Trial will enroll approximately 600 patients at up to 60 centers with anterior basal ganglia hemorrhage to surgery using FDA-cleared technology versus best medical management alone. Enrollment is targeted to begin in March 2025.
The REACH Registry will prospectively enroll patients with lobar hemorrhage, thalamic hemorrhage, or non-REACH trial qualifying anterior basal ganglia hemorrhage and whom undergo minimally invasive parafasicular surgery. A subset of patients who do not undergo surgery will also be enrolled. At least 1800 patients will be included in the registry.The companion registry will prospectively build a comprehensive data repository with long term outcomes, guiding future clinical practices and promoting broader adoption of MIPS for patients with spontaneous ICH.
| Principal Investigators | Gustavo Pradilla, Jonathan Ratcliff, Alex Hall |